11 Dec 2009 07:00
Immunodiagnostic Systems Holdings plc
Appointment of Non-Executive Director
Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces the appointment of Dr. Patrik Olof Dahlén as a Non-Executive Director with immediate effect.
Dr. Dahlén, aged 47, has over 20 years of experience in the diagnostics and life science industries and recently became Chief Executive Officer of Chempaq A/S, the Denmark-based Point of Care diagnostics company (www.chempaq.com) in November 2009.
Previously Dr. Dahlén was CEO of Dako A/S having joined the Denmark based company in 2005. During this time he repositioned the company as a global leader in cancer and companion diagnostics leading up to its sale to EQT, a private equity company, in 2007. Before joining Dako, Dr. Dahlén was CEO of BioImage A/S from 2001.
Earlier in his career Dr. Dahlén moved from research through to international senior management positions within Wallac (now part of PerkinElmer Inc.), becoming Senior Vice President of PerkinElmer Inc and holding the role of President at PerkinElmer Life Sciences Inc. He has a Ph.D. in Biochemistry from Turku University in Finland.
Dr. Dahlén also serves as Chairman of OLink Biosciences (Uppsala, Sweden) and has been a board member of several companies including Cantion and DakoCytomation, both in Copenhagen and DxS Diagnostics in Manchester, UK.
David Evans, Chairman of IDS, said, "We are very pleased to appoint Patrik to the Board. Patrik has huge international experience in the diagnostic sector with both large and instrument based IVD companies and will be invaluable to the IDS Board as it continues to execute its growth plans."
Aim Rules Disclosures:
| Current Directorships | Previous Directorships (last five years) |
| Chempaq A/S | BioImage A/S |
| DxS Diagnostics Ltd | Cantion A/S |
| OLink AB | DakoCytomation A/S |
| Proxeon A/S | Dako A/S |
There are no further matters in connection with the appointment of Dr. Dahlén to be disclosed under Schedule Two, paragraph (g) of the AIM Rules.
Enquiries:
| Immunodiagnostic Systems Holdings Plc | Tel: 0191 519 0660 |
| David Evans, Chairman | |
| Roger Duggan, CEO | |
| Brewin Dolphin Investment Banking | Tel: 0845 213 4730 |
| Andrew Emmott Sean Wyndham-Quin | |
| Walbrook PR Ltd | Tel: 020 7933 8787 |
| Paul McManus | Mob: 07980 541 893 |
| paul.mcmanus@walbrookpr.com |